Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli (NA), Italy.
Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Br J Pharmacol. 2019 May;176(10):1568-1584. doi: 10.1111/bph.14460. Epub 2018 Sep 9.
Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo.
Using quantitative PCR, western blots and [Ca ] measurements, we explored the effects of CBD and CBDV on the differentiation of both murine and human skeletal muscle cells as well as their potential interaction with TRP channels. Male dystrophic mdx mice were injected i.p. with CBD or CBDV at different stages of the disease. After treatment, locomotor tests and biochemical analyses were used to evaluate their effects on inflammation and autophagy.
CBD and CBDV promoted the differentiation of murine C2C12 myoblast cells into myotubes by increasing [Ca ] mostly via TRPV1 activation, an effect that undergoes rapid desensitization. In primary satellite cells and myoblasts isolated from healthy and/or DMD donors, not only CBD and CBDV but also THCV promoted myotube formation, in this case, mostly via TRPA1 activation. In mdx mice, CBD (60 mg·kg ) and CBDV (60 mg·kg ) prevented the loss of locomotor activity, reduced inflammation and restored autophagy.
We provide new insights into plant cannabinoid interactions with TRP channels in skeletal muscle, highlighting a potential opportunity for novel co-adjuvant therapies to prevent muscle degeneration in DMD patients.
This article is part of a themed section on 8 European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.
杜氏肌营养不良症(DMD)是由于抗肌萎缩蛋白缺失引起的,导致慢性炎症和不可逆转的骨骼肌退化。此外,自噬功能的损害极大地加剧了肌肉损伤的恶化。我们探索了使用大麻中的非致幻化合物大麻二酚(CBD)、大麻二酚酸(CBDV)和四氢大麻二酚酸(THCV)来减轻炎症、恢复功能性自噬并在体内积极增强肌肉功能的可能性。
使用定量 PCR、western blot 和 [Ca ]测量,我们探讨了 CBD 和 CBDV 对鼠和人骨骼肌细胞分化的影响,以及它们与 TRP 通道的潜在相互作用。雄性 DMD mdx 小鼠在疾病的不同阶段经腹腔注射 CBD 或 CBDV。治疗后,通过运动测试和生化分析评估它们对炎症和自噬的影响。
CBD 和 CBDV 通过增加 [Ca ]促进鼠 C2C12 成肌细胞向肌管分化,这种作用主要通过 TRPV1 激活,这种作用会迅速脱敏。在来自健康和/或 DMD 供体的原代卫星细胞和成肌细胞中,不仅 CBD 和 CBDV 而且 THCV 也促进肌管形成,在这种情况下,主要通过 TRPA1 激活。在 mdx 小鼠中,CBD(60mg·kg )和 CBDV(60mg·kg )防止运动活动丧失,减少炎症并恢复自噬。
我们提供了植物大麻素与骨骼肌中 TRP 通道相互作用的新见解,强调了一种新的辅助治疗机会,可以预防 DMD 患者的肌肉退化。
本文是关于 8 欧洲大麻素研究研讨会的主题部分的一部分。要查看本部分中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc.html。